Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?

Int J Mol Sci. 2021 Jul 31;22(15):8281. doi: 10.3390/ijms22158281.

Abstract

Chemoresistance of germ cell tumors (GCTs) represents an intensively studied property of GCTs that is the result of a complicated multifactorial process. One of the driving factors in this process is the tumor microenvironment (TME). Intensive crosstalk between the DNA damage/DNA repair pathways and the TME has already been reported. This study aimed at evaluating the interplay between the immune TME and endogenous DNA damage levels in GCT patients. A cocultivation system consisting of peripheral blood mononuclear cells (PBMCs) from healthy donors and GCT cell lines was used in an in vitro study. The patient cohort included 74 chemotherapy-naïve GCT patients. Endogenous DNA damage levels were measured by comet assay. Immunophenotyping of leukocyte subpopulations was performed using flow cytometry. Statistical analysis included data assessing immunophenotypes, DNA damage levels and clinicopathological characteristics of enrolled patients. The DNA damage level in PBMCs cocultivated with cisplatin (CDDP)-resistant GCT cell lines was significantly higher than in PBMCs cocultivated with their sensitive counterparts. In GCT patients, endogenous DNA damage levels above the cutoff value were independently associated with increased percentages of natural killer cells, CD16-positive dendritic cells and regulatory T cells. The crosstalk between the endogenous DNA damage level and specific changes in the immune TME reflected in the blood of GCT patients was revealed. The obtained data contribute to a deeper understanding of ongoing interactions in the TME of GCTs.

Keywords: DNA damage level; germ cell tumors; immune microenvironment; tumor microenvironment.

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / immunology
  • Cell Line, Tumor
  • Cisplatin / therapeutic use
  • DNA Damage*
  • Drug Resistance, Neoplasm
  • Humans
  • Leukocytes, Mononuclear / classification
  • Leukocytes, Mononuclear / immunology*
  • Male
  • Middle Aged
  • Testicular Neoplasms / drug therapy
  • Testicular Neoplasms / genetics
  • Testicular Neoplasms / immunology*
  • Testicular Neoplasms / pathology
  • Tumor Microenvironment / immunology*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cisplatin